Form 4: Citius Oncology CEO Boosts Stake with New Stock Awards

Citius Oncology's CEO, Leonard L. Mazur, reported the acquisition of 1.7 million restricted common shares and holds significant stock options, reflecting ongoing equity compensation.

Summary

• CEO Leonard L. Mazur acquired 1,700,000 shares of Citius Oncology, Inc. common stock on September 19, 2025, as restricted stock awards.
• These restricted shares will vest in three substantially equal installments on the first, second, and third anniversaries of the grant date, contingent on his continuous service to the company or a related entity.
• Mazur also holds 800,000 stock options with an exercise price of $1.07, granted on December 12, 2024, which will vest 1/3 on each of the one-year, two-year, and three-year anniversaries of the grant date, subject to continuous service.
• Additionally, he holds 3,700,000 stock options with an exercise price of $2.15, granted on July 5, 2023, which vest over three years, beginning with 1/36th monthly for the first year, and then 1/3 each on the second and third anniversaries of the grant date, subject to continuous service.

Sentiment

Score: 6

Explanation: The filing reports significant equity compensation grants to the CEO, which aligns management's interests with long-term shareholder value. While not a direct open-market purchase, these grants increase the CEO's beneficial ownership and commitment to the company's future.

Positives

• CEO Leonard L. Mazur's acquisition of 1,700,000 restricted common shares significantly increases his direct beneficial ownership, aligning his interests with shareholders.
• The vesting schedules for both restricted stock and stock options, tied to continuous service, incentivize long-term commitment and performance from the Chief Executive Officer.

Negatives

• NA

Risks

• The vesting of restricted stock and stock options is contingent upon the Reporting Person's continuous service to Citius Oncology, Inc. or a Related Entity, meaning unvested awards could be forfeited if service ceases.

Future Outlook

The restricted stock awards granted on September 19, 2025, are scheduled to vest in three substantially equal installments on the first, second, and third anniversaries of the grant date. The stock options granted on December 12, 2024, are scheduled to vest 1/3 on each of the one-year, two-year, and three-year anniversaries of the grant date. The stock options granted on July 5, 2023, are scheduled to vest 1/36th monthly for the first year, and 1/3 each on the second and third anniversaries of the grant date.

Management Comments

• NA

Industry Context

This filing reflects standard equity compensation practices for executive leadership within the biotechnology or pharmaceutical industry, aiming to align executive incentives with long-term shareholder value through restricted stock and stock option grants.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The grants of restricted stock and stock options to CEO Leonard L. Mazur represent compensation arrangements between the company and a key executive.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's financial interests with long-term shareholder value due to significant equity grants with vesting conditions.
• Employees: The CEO's long-term commitment, as evidenced by these grants, may signal stability and strategic direction for the company.

Next Steps

• Vesting of 1,700,000 restricted stock awards on the first, second, and third anniversaries of September 19, 2025.
• Vesting of 800,000 stock options on the one-year, two-year, and three-year anniversaries of December 12, 2024.
• Vesting of 3,700,000 stock options monthly for the first year and then on the second and third anniversaries of July 5, 2023.

Key Dates

Recommendation

The filing indicates a significant increase in the CEO's beneficial ownership through equity compensation, aligning his incentives with the company's long-term performance. This is generally a positive signal for investor confidence, suggesting management's commitment. However, without broader financial performance data or strategic updates, a definitive 'buy' or 'sell' recommendation cannot be made solely based on this insider transaction report. Therefore, maintaining a 'hold' position is prudent, awaiting further comprehensive financial disclosures.

Keywords

Citius Oncology, CTOR, Leonard L. Mazur, insider ownership, equity compensation, restricted stock, stock options, CEO